Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma - PubMed (original) (raw)
. 2000 Jul 15;96(2):384-92.
Affiliations
- PMID: 10887096
Free article
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
V Kunzmann et al. Blood. 2000.
Free article
Abstract
Bisphosphonates are well-known inhibitors of osteoclastic bone resorption, but recent clinical reports support the possibility of direct or indirect antitumor effects by these compounds. Because bisphosphonates share structural homologies with recently identified gamma delta T-cell ligands, we examined the stimulatory capacity of bisphosphonates to gamma delta T cells and determined whether gamma delta T-cell stimulation by bisphosphonates could be exploited to generate antiplasma cell activity in multiple myeloma (MM). All tested aminobisphosphonates (alendronate, ibandronate, and pamidronate) induced significant expansion of gamma delta T cells (V gamma 9V delta 2++ subset) in peripheral blood mononuclear cell cultures of healthy donors at clinically relevant concentrations (half-maximal activity, 0.9-4 mcmol/L). The proliferative response of gamma delta T cells to aminobisphosphonates was IL-2 dependent, whereas activation of gamma delta T cells (up-regulation of CD25 and CD69) occurred in the absence of exogenous cytokines. Pamidronate-activated gamma delta T cells produced cytokines (ie, interferon [IFN]-gamma) and exhibited specific cytotoxicity against lymphoma (Daudi) and myeloma cell lines (RPMI 8226, U266). Pamidronate-treated bone marrow (BM) cultures of 24 patients with MM showed significantly reduced plasma cell survival compared with untreated cultures, especially in cultures in which activation of BM-gamma delta T cells was evident (14 of 24 patients with MM). gamma delta T-cell depletion from BM cultures completely abrogated the cytoreductive effect on myeloma cells in 2 of 3 tested patients with MM. These results show that aminobisphosphonates stimulating gamma delta T cells have pronounced effects on the immune system, which might contribute to the antitumor effects of these drugs. (Blood. 2000;96:384-392)
Comment in
- Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate.
Schilbach K, Geiselhart A, Handgretinger R. Schilbach K, et al. Blood. 2001 May 1;97(9):2917-8. doi: 10.1182/blood.v97.9.2917. Blood. 2001. PMID: 11345090 No abstract available.
Similar articles
- Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Wilhelm M, et al. Blood. 2003 Jul 1;102(1):200-6. doi: 10.1182/blood-2002-12-3665. Epub 2003 Mar 6. Blood. 2003. PMID: 12623838 Clinical Trial. - Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Das H, Wang L, Kamath A, Bukowski JF. Das H, et al. Blood. 2001 Sep 1;98(5):1616-8. doi: 10.1182/blood.v98.5.1616. Blood. 2001. PMID: 11520816 - Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells.
Massaia M, Attisano C, Peola S, Montacchini L, Omedé P, Corradini P, Ferrero D, Boccadoro M, Bianchi A, Pileri A. Massaia M, et al. Blood. 1993 Sep 15;82(6):1787-97. Blood. 1993. PMID: 8400233 - Immunological Prognostic Factors in Multiple Myeloma.
Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, Góźdź S, Roliński J, Niedźwiedzka-Rystwej P. Bębnowska D, et al. Int J Mol Sci. 2021 Mar 30;22(7):3587. doi: 10.3390/ijms22073587. Int J Mol Sci. 2021. PMID: 33808304 Free PMC article. Review. - Orbital Inflammation Caused by Aminobisphosphonates.
Gonzalez Barlatay J, Pagano Boza C, Hernandez Gauna GV, Premoli JE. Gonzalez Barlatay J, et al. J Ophthalmic Vis Res. 2022 Jan 21;17(1):118-122. doi: 10.18502/jovr.v17i1.10176. eCollection 2022 Jan-Mar. J Ophthalmic Vis Res. 2022. PMID: 35371416 Free PMC article. Review.
Cited by
- Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?
Clark EM, Durup D. Clark EM, et al. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):11-6. doi: 10.1177/1759720X14566424. Ther Adv Musculoskelet Dis. 2015. PMID: 25650170 Free PMC article. Review. - Potential of gamma/delta T cells for solid tumor immunotherapy.
Zhu D, Ren X, Xie W, Chen J, Liang S, Jiang M, Wang J, Zheng Z. Zhu D, et al. Front Immunol. 2024 Aug 26;15:1466266. doi: 10.3389/fimmu.2024.1466266. eCollection 2024. Front Immunol. 2024. PMID: 39253082 Free PMC article. Review. - Pamidronate treatment in rheumatology practice: a comprehensive review.
Slobodin G, Rosner I, Feld J, Rimar D, Rozenbaum M, Boulman N, Odeh M. Slobodin G, et al. Clin Rheumatol. 2009 Dec;28(12):1359-64. doi: 10.1007/s10067-009-1256-2. Epub 2009 Aug 19. Clin Rheumatol. 2009. PMID: 19690938 Review. - Human γδ T lymphocytes for immunotherapeutic strategies against cancer.
Kabelitz D. Kabelitz D. F1000 Med Rep. 2010 Jun 23;2:45. doi: 10.3410/M2-45. F1000 Med Rep. 2010. PMID: 20948839 Free PMC article. - Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis.
Li Y, Yang D, Chen P, Yin X, Sun J, Li H, Ren G. Li Y, et al. Aging (Albany NY). 2019 Aug 24;11(16):6286-6311. doi: 10.18632/aging.102188. Epub 2019 Aug 24. Aging (Albany NY). 2019. PMID: 31446432 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical